tralokinumab is an approved drug (EMA & FDA (2021))
Compound class:
Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (EMA & FDA (2021)) |
International Nonproprietary Names | |
INN number | INN |
9235 | tralokinumab |
Synonyms | |
Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 171 |
Other databases | |
GtoPdb PubChem SID | 249565681 |
Search PubMed clinical trials | tralokinumab |
Search PubMed titles | tralokinumab |
Search PubMed titles/abstracts | tralokinumab |
Wikipedia | Tralokinumab |